EMD Millipore has opened a Biopharmaceutical Technical and Training Center in Shanghai. The 28,000 square foot facility will provide support, training, and validation services to EMD Millipore’s biopharmaceutical customers with operations in China.
“We are responding to China’s commitment to strengthen regulatory requirements designed to ensure drug safety,” says Jean-Paul Mangeolle, head of EMD Millipore’s process solutions business. “Our new Biopharmaceutical Technical Center is unique in that we can support and even train our pharmaceutical customers to meet the new Chinese and global regulations.”
The Chinese SFDA and Peking University are among initial institutions that will use the technical center for training courses specifically created for GMP training and aseptic process manufacturing.
The center is located in Zhangjiang Hi-Tech Park and will support biopharmaceutical manufacturers in the area. The facility will allow local and regional customers to investigate, explore, and optimize their upstream and downstream processes as well as environmental monitoring processes with the support of EMD Millipore’s local, regional, and international experts.
The company operates similar facilities in Singapore, Japan, India, France, North America, and Brazil. EMD Millipore was established as the life science division of Merck KGaA after Merck bought Millipore for $7 billion last year. The segment combines Merck’s EMD Chemicals business, located in New Jersey, and Millipore.